0.018
0.00 (0.00%)
| Penutupan Terdahulu | 0.018 |
| Buka | 0.018 |
| Jumlah Dagangan | 10,000 |
| Purata Dagangan (3B) | 211,811 |
| Modal Pasaran | 15,983,261 |
| Harga / Jualan (P/S) | 2.34 |
| Harga / Buku (P/B) | 5.05 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 23 Aug 2024 |
| Margin Keuntungan | -138.79% |
| Margin Operasi (TTM) | -96.82% |
| EPS Cair (TTM) | -0.010 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 39.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 140.10% |
| Nisbah Semasa (MRQ) | 0.780 |
| Aliran Tunai Operasi (OCF TTM) | -5.57 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.84 M |
| Pulangan Atas Aset (ROA TTM) | -30.36% |
| Pulangan Atas Ekuiti (ROE TTM) | -173.93% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (SG) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | IX Biopharma | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| IX BIOPHARMA | 16 M | - | - | 5.05 |
| TJ DARENTANG USD | 3 B | 50.00% | 5.44 | 1.86 |
|
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 50.56% |
| % Dimiliki oleh Institusi | 0.09% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Lee (Yip Hang Eddy) | 04 Sep 2024 | 217,000,852 (24.57%) |
| HRT Corporation Pte. Ltd. | 04 Sep 2024 | 66,748,029 (7.56%) |
| Tang (Choy Leng Jane) | 04 Sep 2024 | 22,793,565 (2.58%) |
| Narulla (Jaspal Singh) | 04 Sep 2024 | 20,727,047 (2.35%) |
| Tan (See Tee) | 04 Sep 2024 | 17,470,800 (1.98%) |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 23 May 2025 | Pengumuman | General Announcement::Notice of End of Conversion Period and Maturity Date of Convertible Bonds |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |